Kiora director granted options on 40,000 shares

Kiora Pharmaceuticals director Praveen Tyle received a grant of stock options as equity compensation.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kiora Pharmaceuticals director Praveen Tyle received a grant of stock options as equity compensation. The award covers options on 40,000 shares of common stock at an exercise price of $2.63 per share under the 2024 Equity Incentive Plan.

The options become fully exercisable on June 10, 2027 and expire on June 10, 2036. Following this grant, Tyle holds options on 40,000 shares directly, with no open-market buying or selling reported in this filing.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider TYLE PRAVEEN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 40,000 contracts (Direct)

Footnotes (1)

F1. The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.

Key Figures

Options granted: 40,000 shares Exercise price: $2.63 per share Vesting date: June 10, 2027 +2 more

5 metrics

Options granted 40,000 shares Stock options on common stock granted June 10, 2026

Exercise price $2.63 per share Strike price of the stock option grant

Vesting date June 10, 2027 Date options become fully exercisable

Expiration date June 10, 2036 Option term under 2024 Equity Incentive Plan

Holdings after grant 40,000 options Total derivative securities following the transaction

Key Terms

Stock Option (right to buy), 2024 Equity Incentive Plan, exercise price, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

2024 Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan."

exercise price financial

"conversion_or_exercise_price: "2.6300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-10T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kiora Pharmaceuticals (KPRX) report for Praveen Tyle?

Kiora Pharmaceuticals reported that director Praveen Tyle received a grant of stock options for 40,000 shares of common stock. The options are a compensation award, not an open-market trade, and were issued under the company’s 2024 Equity Incentive Plan.

What is the exercise price of Praveen Tyle’s new Kiora (KPRX) stock options?

The new stock options granted to director Praveen Tyle have an exercise price of $2.63 per share. This is the price he must pay to purchase Kiora common shares if he chooses to exercise the options after they vest.

When do Praveen Tyle’s Kiora (KPRX) stock options vest and become exercisable?

The stock options granted to Praveen Tyle will become fully exercisable on June 10, 2027. Until that vesting date, he cannot exercise them to purchase Kiora common shares, even though the grant has already been awarded.

When do the newly granted Kiora (KPRX) stock options to Praveen Tyle expire?

The options granted to director Praveen Tyle expire on June 10, 2036. If they are not exercised by that date, they will lapse and become worthless, which is standard for long-term equity incentive grants like these.

How many Kiora (KPRX) derivative securities does Praveen Tyle hold after this Form 4?

After this grant, Praveen Tyle holds stock options covering 40,000 shares of Kiora common stock. The Form 4 indicates these options are held directly and are the only derivative position reported in this filing for him.

Were Praveen Tyle’s Kiora (KPRX) options acquired through market buying or as compensation?

The filing shows Praveen Tyle acquired the options as a compensation grant under Kiora’s 2024 Equity Incentive Plan. The transaction code is “A,” indicating a grant or award, not an open-market purchase or sale of existing shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/12/2026 - 04:13 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TYLE PRAVEEN

(Last)

(First)

(Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS

CALIFORNIA

92024

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.63	06/10/2026		A		40,000		06/10/2027⁽¹⁾	06/10/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.

Remarks:

	/s/ Melissa Tosca, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR